SCHEDULE 13D: Caribou Biosciences CEO and Family Trust Increase Stake to 5%, Signaling Confidence

Caribou Biosciences, Inc. CEO Rachel E. Haurwitz and The City Canyon Family Trust have increased their beneficial ownership in the company to 5%, reflecting a renewed significant insider stake.

Summary

• Rachel E. Haurwitz, CEO of Caribou Biosciences, Inc., along with The City Canyon Family Trust and Felix Adler, M.D., collectively reported beneficial ownership of 4,716,003 shares of Caribou Biosciences common stock, representing 5% of the outstanding shares.
• This filing marks a return to beneficial ownership exceeding 5% after a previous 'exit filing' by the Reporting Persons.
• The shares are held through The City Canyon Family Trust (3,369,395 shares), direct ownership by Dr. Haurwitz (69,675 shares, community property with Dr. Adler), and shares underlying stock options and RSUs exercisable or vesting within 60 days (1,276,933 shares).
• The percentage is based on 93,004,602 shares outstanding as of April 15, 2025, as reported in the Issuer's definitive proxy statement.
• The City Canyon Family Trust purchased 20,000 shares of the Issuer's common stock on March 14, 2025, at a weighted average price of $1.02 per share.
• A previously adopted 10b5-1 sales plan by the Trust, which intended to sell up to 540,000 shares through December 12, 2025, was terminated effective March 18, 2025, without any shares being sold.

Sentiment

Score: 7

Explanation: The document indicates increased insider ownership and direct insider buying, coupled with the termination of a potential selling plan, which are generally positive signals for investors, suggesting confidence from key management.

Positives

• The CEO, Rachel E. Haurwitz, and her associated trust have increased their beneficial ownership to 5%, signaling strong insider confidence in Caribou Biosciences.
• The City Canyon Family Trust recently purchased 20,000 shares of the company's common stock at a weighted average price of $1.02 per share on March 14, 2025, indicating direct insider buying.
• A 10b5-1 sales plan, which would have allowed the sale of up to 540,000 shares, was terminated without any sales, potentially reducing future selling pressure from the Trust.
• Dr. Haurwitz continues to receive equity awards (RSUs) and holds unvested awards, aligning her long-term interests with shareholder value.

Negatives

• The document does not explicitly state any negative financial or operational outcomes. The termination of a 10b5-1 plan without sales is not inherently negative, but it's not a clear positive either, as it simply means the planned sales did not occur.

Risks

• The Reporting Persons may acquire additional securities or dispose of all or a portion of their holdings in the future, which could impact share price.
• The number of shares sold under Dr. Haurwitz's sell-to-cover arrangement for tax withholding on RSUs is not currently determinable and will vary based on vesting conditions, market price, and future RSU grants, potentially leading to future sales.

Future Outlook

The Reporting Persons intend to continuously review their investment in Caribou Biosciences, Inc. and may acquire additional securities or dispose of existing holdings in the future, subject to the Issuer's Insider Trading Policy. Dr. Haurwitz's beneficial ownership may increase as her equity awards, including stock options and RSUs, continue to vest. The Reporting Persons may adopt other 10b5-1 plans from time to time in the future.

Management Comments

• "Dr. Haurwitz's principal occupation is President and Chief Executive Officer of the Issuer... and acquired her securities in that capacity."
• "As a result [of Dr. Haurwitz's role], the Reporting Persons may have influence over the corporate activities of the Issuer."

Industry Context

This Schedule 13D filing primarily concerns changes in insider ownership and does not provide broader industry trends or competitive analysis. Caribou Biosciences, Inc. is identified as a clinical-stage CRISPR genome-editing biotechnology company, operating within the innovative and high-growth biotechnology sector.

Comparison to Industry Standards

• This filing is a standard disclosure for beneficial ownership changes exceeding 5% by an individual or group, as required by SEC regulations.
• The specific financial metrics provided (e.g., share count, purchase price) are internal to Caribou Biosciences and the reporting persons, and the document does not offer comparative data against other biotechnology companies or industry benchmarks. Therefore, a direct comparison to industry standards for financial performance is not applicable based on this document.

Corporate Governance

Related Party Transactions

• The transfer of 3,349,395 shares of the Issuer's common stock from Dr. Haurwitz to The City Canyon Family Trust, for which Dr. Haurwitz and Dr. Adler serve as co-trustees.
• A promissory note (2018 Loan) in the principal amount of $1,100,000 from the Issuer to Dr. Haurwitz, which was repaid in full with interest.
• The granting of stock options and Restricted Stock Units (RSUs) by the Issuer to Dr. Haurwitz, which contribute to her beneficial ownership.

Stakeholder Impact

• Shareholders: Increased insider ownership and recent insider buying may be viewed positively, signaling management's confidence and alignment with shareholder interests. The termination of a 10b5-1 sales plan removes potential selling pressure.
• Employees: Dr. Haurwitz's continued role as CEO and receipt of equity awards suggest stability in leadership.

Next Steps

• The Reporting Persons intend to continuously review their investment in Caribou Biosciences, Inc.
• They may acquire additional securities or dispose of existing holdings in the future.
• Dr. Haurwitz's beneficial ownership is expected to increase as her granted equity awards (RSUs) vest.
• The Reporting Persons may adopt other 10b5-1 plans in the future.

Key Dates

Recommendation

Keywords

Caribou Biosciences, CRISPR genome-editing, Biotechnology, SEC filing, Schedule 13D, Beneficial ownership, Insider ownership, Rachel E. Haurwitz, Stock options, Restricted Stock Units (RSUs), 10b5-1 plan, Insider buying